Pharmacological and genetic perturbation establish SIRT5 as a promising target in breast cancer

Yashira L. Negrón Abril,Irma R. Fernandez,Jun Young Hong,Ying-Ling Chiang,Dennis A. Kutateladze,Qingjie Zhao,Min Yang,Jing Hu,Sushabhan Sadhukhan,Bo Li,Bin He,Brenna Remick,Jessica Jingyi Bai,James Mullmann,Fangyu Wang,Viviana Maymi,Ravi Dhawan,Johan Auwerx,Teresa Southard,Richard A. Cerione,Hening Lin,Robert S. Weiss

DOI: https://doi.org/10.1038/s41388-020-01637-w

IF: 8.756

2021-01-21

Oncogene

Abstract:SIRT5 is a member of the sirtuin family of NAD⁺-dependent protein lysine deacylases implicated in a variety of physiological processes. SIRT5 removes negatively charged malonyl, succinyl, and glutaryl groups from lysine residues and thereby regulates multiple enzymes involved in cellular metabolism and other biological processes. SIRT5 is overexpressed in human breast cancers and other malignancies, but little is known about the therapeutic potential of SIRT5 inhibition for treating cancer. Here we report that genetic <i>SIRT5</i> disruption in breast cancer cell lines and mouse models caused increased succinylation of IDH2 and other metabolic enzymes, increased oxidative stress, and impaired transformation and tumorigenesis. We, therefore, developed potent, selective, and cell-permeable small-molecule SIRT5 inhibitors. SIRT5 inhibition suppressed the transformed properties of cultured breast cancer cells and significantly reduced mammary tumor growth in vivo, in both genetically engineered and xenotransplant mouse models. Considering that <i>Sirt5</i> knockout mice are generally normal, with only mild phenotypes observed, these data establish SIRT5 as a promising target for treating breast cancer. The new SIRT5 inhibitors provide useful probes for future investigations of SIRT5 and an avenue for targeting SIRT5 as a therapeutic strategy.

oncology,genetics & heredity,biochemistry & molecular biology,cell biology

What problem does this paper attempt to address?

The paper aims to explore the role of SIRT5 in breast cancer and its potential as a therapeutic target. Specifically, the paper addresses the following key issues:

1. **Overexpression of SIRT5 in Breast Cancer**: The study found that SIRT5 is overexpressed in human breast cancer and is associated with poorer patient prognosis. This suggests that SIRT5 may be an important molecular marker for breast cancer.

2. **Impact of SIRT5 Inhibition on Cell Proliferation**: Through gene knockout experiments, researchers discovered that the absence of SIRT5 significantly inhibits the proliferation and anchorage-independent growth of breast cancer cells, indicating that SIRT5 is crucial for maintaining the malignant phenotype of tumor cells.

3. **Impact of SIRT5 Inhibition on Mouse Models**: In the MMTV-PyMT transgenic mouse model, the absence of SIRT5 delayed the onset of mammary tumors and reduced the burden of lung metastasis. These results further support the potential of SIRT5 as a therapeutic target for breast cancer.

4. **Development of Selective SIRT5 Inhibitors**: To validate the effectiveness of SIRT5 as a drug target, researchers designed and synthesized various cell-permeable SIRT5 inhibitors and demonstrated that these inhibitors could inhibit the growth of breast cancer cells both in vitro and in vivo.

In summary, the paper demonstrates the important role of SIRT5 in breast cancer through pharmacological and genetic approaches and, for the first time, shows the potential efficacy of SIRT5 inhibitors in the treatment of breast cancer.